Intellia CRISPR-Cas9 platform creates gene insertion edits in vivo

Intellia Therapeutics Inc. (NASDAQ:NTLA) presented data at the European Society of Gene and Cell Therapy meeting in Lausanne, Switzerland, showing that its CRISPR-Cas9 platform is capable of creating both gene disruption and the more challenging gene insertion edits in vivo (see "Intellia's Delivery Address").

At this year’s meeting, the company reported that it inserted two genes into mouse genomes, resulting in at least therapeutic levels of protein production...